An­nex­on grabs $75M to pay for push in­to PhII stud­ies for C1q drugs

Back when Bain’s Ricky Sun worked at Bio­gen, he gained a deep ap­pre­ci­a­tion for the role of the clas­si­cal com­ple­ment path­way in neu­rode­gen­er­a­tion. And now he’s put that ed­u­ca­tion to work, help­ing steer a syn­di­cate of in­vestors who are mak­ing a $75 mil­lion bet on An­nex­on’s work in the field.

“They know com­ple­ment well,” says Sun, a part­ner at Bain Cap­i­tal Life Sci­ences, which will add this ven­ture in its “in­flec­tion cap­i­tal” buck­et of in­vest­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER